Long non-coding RNA SNHG12promotes the proliferation and migration of glioma cells by binding to HuR

Lei,Wei; Wang,Zhi-Long; Feng,He-Jun; Lin,Xiang-Dan; Li,Chuang-Zhong; Fan,Di

doi:10.3892/ijo.2018.4478

Long non-coding RNA SNHG12promotes the proliferation and migration of glioma cells by binding to HuR

Authors:
- Wei Lei
- Zhi-Long Wang
- He-Jun Feng
- Xiang-Dan Lin
- Chuang-Zhong Li
- Di Fan
View Affiliations

Affiliations: Institute of Neurology, General Hospital of Shenyang Military Command, Shengyang, Liaoning 110000, P.R. China, Graduate School of Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Graduate School of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: July 11, 2018 https://doi.org/10.3892/ijo.2018.4478
Pages: 1374-1384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non-coding RNAs (lncRNAs) play important roles in biological processes and provide a novel approach with which to understand the molecular mechanisms responsible for glioma. Previous studies have demonstrated that lncRNA small nucleolar RNA host gene 12 (SNHG12) is involved in cell growth and migration. However, the accurate expression pattern of SNHG12 in glioma and the possible associations between this pattern and the clinicopathological characteristics of glioma cohorts are not yet known. The present study investigated the role of lncRNA SNHG12 in the development and progression of glioma, as well as the potential diagnostic value of SNHG12 in patients with glioma. The levels of SNHG12 were detected in resected specimens from patients and in glioma cell lines using reverse transcription-quantitative polymerase chain reaction. The potential effects of SNHG12 on the viability, mobility and apoptosis of glioma cells were evaluated using in vitro assays. The association between SNHG12 and Hu antigen R (HuR) was also determined using RNA immunoprecipitation (RIP) and RNA pull-down assays. The results revealed that SNHG12 was significantly upregulated in glioma tissues and cell lines. High levels of SNHG12 were associated with the deterioration of patients with glioma. Patients with high levels of SNHG12 exhibited a reduced 5-year overall survival rate (compared to those with lower levels), particularly in cohorts with high-grade carcinoma (III-IV). The silencing of SNHG12 expression by RNA interference led to a reduced viability and mobility, and in an increased apoptosis of human glioma cells. Furthermore, RIP and RNA pull-down assays demonstrated that SNHG12 was associated with and was stabilized by HuR. The findings of the present study thus identify a novel therapeutic target in glioma.

View Figures

View References

1	Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, et al European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sanai N, Polley MY, McDermott MW, Parsa AT and Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Diederichs S: The four dimensions of noncoding RNA conservation. Trends Genet. 30:121–123. 2014. View Article : Google Scholar : PubMed/NCBI
5	Shi X, Sun M, Liu H, Yao Y and Song Y: Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett. 339:159–166. 2013. View Article : Google Scholar : PubMed/NCBI
6	Huang JL, Zheng L, Hu YW and Wang Q: Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 35:507–514. 2014. View Article : Google Scholar
7	Fatica A and Bozzoni I: Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet. 15:7–21. 2014. View Article : Google Scholar
8	Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zhai W, Li X, Wu S, Zhang Y, Pang H and Chen W: Microarray expression profile of lncRNAs and the upregulated ASLNC04080 lncRNA in human endometrial carcinoma. Int J Oncol. 46:2125–2137. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ruan W, Wang P, Feng S, Xue Y and Li Y: Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells. Tumour Biol. 37:4065–4073. 2016. View Article : Google Scholar
11	Gong Z, Zhang S, Zeng Z, Wu H, Yang Q, Xiong F, Shi L, Yang J, Zhang W, Zhou Y, et al: LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2. PLoS One. 9:e1106742014. View Article : Google Scholar : PubMed/NCBI
12	Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
13	Brennan CM and Steitz JA: HuR and mRNA stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
14	Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, Wheeler C and Nabors LB: The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 9:648–659. 2011. View Article : Google Scholar : PubMed/NCBI
15	Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H and Ristimäki A: Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 13:6959–6963. 2007. View Article : Google Scholar : PubMed/NCBI
16	Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S, Dietel M and Weichert W: Expression of the ELAV-like protein HuR in human colon cancer: Association with tumor stage and cyclooxygenase-2. Mod Pathol. 19:1261–1269. 2006. View Article : Google Scholar : PubMed/NCBI
17	Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R and Ristimäki A: Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 63:7591–7594. 2003.PubMed/NCBI
18	Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M and Brody JR: The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 69:4567–4572. 2009. View Article : Google Scholar : PubMed/NCBI
19	López de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES and Gorospe M: Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene. 22:7146–7154. 2003. View Article : Google Scholar : PubMed/NCBI
20	Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C and Ristimäki A: Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 65:2157–2161. 2005. View Article : Google Scholar : PubMed/NCBI
21	Cho NP, Han HS, Soh Y, Lee KY and Son HJ: Cytoplasmic HuR over-expression is associated withincreased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas. Pathology. 39:545–550. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lim SJ, Kim HJ, Kim JY, Park K and Lee CM: Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol. 26:229–234. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ido K, Nakagawa T, Sakuma T, Takeuchi H, Sato K and Kubota T: Expression of vascular endothelialgrowth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology. 28:604–611. 2008.PubMed/NCBI
24	Ortega AD, Sala S and Espinosa E: Gonzalez-Baron M and Cuezva JM: HuR and the bioenergetics signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis. 29:2053–2061. 2008. View Article : Google Scholar : PubMed/NCBI
25	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW and Figarella-Branger D: World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer; France: 2016
26	Louis DN and Ohgaki H; Wiestler O and Cavenee W: World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer; Lyon: 2007
27	Song S, Fajol A, Tu X, Ren B and Shi S: miR-204 suppresses the development and progression of human glioblastoma by targeting ATF2. Oncotarget. 7:70058–70065. 2016. View Article : Google Scholar : PubMed/NCBI
28	Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S and Ichimura K: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol. 32:22–30. 2015. View Article : Google Scholar
29	Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, et al: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126:267–276. 2013. View Article : Google Scholar : PubMed/NCBI
30	Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, et al: MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer. 131:1104–1113. 2012. View Article : Google Scholar
31	Wang XP, Shan C, Deng XL, Li LY and Ma W: Long non-coding RNA PAR5 inhibits the proliferation and progression of glioma through interaction with EZH2. Oncol Rep. 38:3177–3186. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wang P, Chen D, Ma H and Li Y: LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 8:84086–84101. 2017.PubMed/NCBI
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
34	Wang L, Ye S, Wang J, Gu Z, Zhang Y, Zhang C and Ma X: HuR Stabilizes lnc-Sox5 mRNA to Promote Tongue Carcinogenesis. Biochemistry (Mosc). 82:438–445. 2017. View Article : Google Scholar
35	Zheng J, Liu X, Xue Y, Gong W, Ma J, Xi Z, Que Z and Liu Y: TTBK2 circular RNA promotes glioma malignancy by regulating miR-217/HNF1β/Derlin-1 pathway. J Hematol Oncol. 10:522017. View Article : Google Scholar
36	Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao M, et al: MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 52:1731–1740. 2010. View Article : Google Scholar : PubMed/NCBI
37	He Z, Huang C, Lin G and Ye Y: siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells. Oncol Rep. 35:1933–1940. 2016. View Article : Google Scholar : PubMed/NCBI
38	Chen QN, Wei CC, Wang ZX and Sun M: Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 8:1925–1936. 2017.
39	Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, Wang J, Tan Q, Cheng Y, Xia E, et al: C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. Am J Transl Res. 9:533–545. 2017.PubMed/NCBI
40	Lan T, Ma W, Hong Z, Wu L, Chen X and Yuan Y: Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. J Exp Clin Cancer Res. 36:112017. View Article : Google Scholar : PubMed/NCBI
41	Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, et al: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016. View Article : Google Scholar : PubMed/NCBI
42	Turkalp Z, Karamchandani J and Das S: IDH mutation in glioma: New insights and promises for the future. JAMA Neurol. 71:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI
43	Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
44	Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba I, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, et al: Validation of SCT methylation as a hallmark biomarker for lung cancers. J Thorac Oncol. 11:346–360. 2016. View Article : Google Scholar : PubMed/NCBI
45	Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, et al Nordic Clinical Brain Tumour Study Group (NCBTSG): Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol. 13:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
46	Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, et al NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707–715. 2012. View Article : Google Scholar : PubMed/NCBI
47	Bakheet T, Williams BR and Khabar KS: ARED 3.0: The large and diverse AU-rich transcriptome. Nucleic Acids Res. 34:D111–D114. 2006. View Article : Google Scholar :
48	Katsanou V, Milatos S, Yiakouvaki A, Sgantzis N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger M and Kontoyiannis DL: The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. Mol Cell Biol. 29:2762–2776. 2009. View Article : Google Scholar : PubMed/NCBI
49	Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, Kollias G and Kontoyiannis DL: HuR as a negative posttranscriptional modulator in inflammation. Mol Cell. 19:777–789. 2005. View Article : Google Scholar : PubMed/NCBI
50	Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP and Weller M: BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol. 56:43–49. 2002. View Article : Google Scholar : PubMed/NCBI
51	Bolognani F, Gallani AI, Sokol L, Baskin DS and Meisner-Kober N: mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells. J Neurooncol. 106:531–542. 2012. View Article : Google Scholar